Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in relapsed/refractory primary light-chain amyloidosis
NCT07039578Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gamgertamig in Amyloid Light Chain Amyloidosis (2 arms), sponsored by Keymed Biosciences. Primary endpoint: Efficacy after CM336 treatment at 3 years. Started Jul 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
Amyloid Light Chain Amyloidosis
Beyond the preview
Go deeper on NCT07039578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039578.